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The clinical and electroencephalographic features of a canine
generalized myoclonic epilepsy with photosensitivity and onset in
young Rhodesian Ridgeback dogs (6 wk to 18 mo) are described. A
fully penetrant recessive 4-bp deletion was identified in the DIRAS
family GTPase 1 (DIRAS1) gene with an altered expression pattern
of DIRAS1 protein in the affected brain. This neuronal DIRAS1 gene
with a proposed role in cholinergic transmission provides not only a
candidate for human myoclonic epilepsy but also insights into the
disease etiology, while establishing a spontaneous model for future
intervention studies and functional characterization.
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Dogs provide physiologically relevant models of human dis-ease. Aggressive breeding has resulted in a unique genetic
architecture that facilitates gene discovery (1). Many breeds originate
from a limited number of founder animals and the use of popular
sires is a common practice. As a consequence, each breed represents
an isolated population with high levels of phenotypic homogeneity,
reduced genetic diversity, and enrichment of breed-specific disorders
(2). Hundreds of naturally occurring canine conditions are analogous
to human diseases, such as diabetes, cancers, epilepsies, eye diseases,
autoimmune diseases, and monogenic diseases.
Epilepsy is the most common chronic neurological disease in dogs
(3). A strong genetic background is suspected in many dog breeds
with a high prevalence (4) and several genes have been discovered in
both symptomatic and idiopathic epilepsy. Most of these genes
represent orthologs to the corresponding human epilepsy genes,
such the canine models for progressive myoclonic epilepsy, including
NHLRC1 in Lafora disease (5, 6) and CLN1, CLN2, ATP13A2,
CLN5, CLN6, CLN8, and MFSD8 in different types of neuronal
ceroid lipofuscinosis (1, 7). Only two genes have been associated
with idiopathic epilepsy in dogs, ADAM23 and LGI2 (8, 9).
In this study, we describe a unique model of genetic generalized
epilepsy in Rhodesian Ridgeback (RR) dogs characterized by a
young age of onset. The RR is an African dog breed, originating
from Rhodesia, now Zimbabwe. The breed-defining characteristic is
a dorsal ridge, caused by a lateral instead of caudal orientation of
the hair in this region (10). The RR reflects a mixture of several
European dog breeds and the local ridged Hottentot Khoi dog and
was initially bred for lion hunting (10, 11). The presence of multiple
affected dogs with a distinct phenotype in many litters proposed an
inherited condition, which warranted us to embark a comprehensive
study to describe the clinical features and find the genetic cause.
Results
Generalized Myoclonic Epilepsy with Photosensitivity in Young RR
Dogs. Altogether, we studied 95 RR dogs, of which 24 (15 ma-
les, 9 females) shared a unique epilepsy phenotype of frequent
myoclonic jerks/twitches, with an onset in young dogs (mean 6 mo;
median 3.5 mo; range 6 wk–18 mo) as the outstanding feature.
Eleven dogs were 5- to 18-mo-old (juvenile, adolescence) at age of
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onset, in 12 dogs onset was between 2 and 4 mo of age (corre-
sponding to 2–10 y in humans, childhood), and in one dog it was at 6
wk (infantile). Photosensitivity was reported in eight dogs. The
disease progressed to generalized tonic-clonic seizures (GTCS) in
38% of dogs within 6 mo (median; 1.5–29 mo) after onset of
myoclonic seizures. Owners of three dogs (>8 y of age) reported
that dogs retained normal cognition throughout life.
Myoclonic jerks were described by the owners as severe startling or
even resembling an electric shock. Preceding alterations in behavior
were not observed. Myoclonic twitches mainly occurred when the
animals were in a recumbent position and relaxed, drowsy, or in the
first stages of sleep, and with the eyes either closed or open. Occa-
sionally twitches occurred also when the dogs were sitting, standing,
or walking (Movie S1). No autonomic signs occurred during the
myoclonic seizures. Based on video review, myoclonic jerks were
predominantly confined to the trunk, proximal limb musculature
(especially the thoracic limbs), cervical musculature producing nod-
ding movements of the head (Movie S2), and the face (masticatory
muscles resulting in chewing movements, eyelid and ear twitches).
Myoclonic jerks would often be limited to or start at one side of the
body; however, a consistent side predilection could not be detected.
Intensity varied between events and individual dogs. Some muscle
contractions were rather subtle, with just a small range of motion,
whereas others were very vigorous and at times made the dogs jump
into the air or dash against the floor, wall, or furniture. Although a
single event lasted less than 1 s, twitches often occurred in series as
repetitive myoclonic muscle contractions. GTCS were also frequently
preceded by a series of myoclonic twitches. Some dogs appeared
confused or scared following the episodes and seemed to be very
agitated after the events, rising up and wandering around restlessly.
Hence, sleep appeared impaired in these dogs. Dogs were normal
between events. Owners reported daily (87%) or almost daily (13%;
every second to third day) occurrence of myoclonic twitches with a
frequency of up to 150 twitches per day. Up to 50 jerks per hour were
recorded with EEG in some dogs. Two dogs showed increased
myoclonic jerks during heat (cases 2 and 11). In three siblings (cases
8, 9, and 10) and another dog (case 6) onset of myoclonus was ob-
served 2 d after vaccination. Onset of GTCS appeared to be tem-
porally related to vaccination in another two dogs (cases 6 and 7).
Diagnostic investigations (Table S1) failed to identify any con-
sistent structural abnormalities. A few dogs had potential brain ab-
normalities on neuroimaging evaluations that may be incidental
findings, such as ventricular asymmetry (12) (Table S2). Twenty-one
RRs with myoclonic epilepsy were treated with a variety of antiep-
ileptic drugs (AEDs: phenobarbital, potassium bromide, primidone,
levetiracetam, clonazepam, imepitoin; monotherapy or combina-
tion) in adequate dosages and with serum concentrations (pheno-
barbital: mean 28.6 mg/L; potassium bromide: mean 1,353 mg/L)
within therapeutic range (13). Levetiracetam, which is also an ef-
fective drug for juvenile myoclonic epilepsy (JME) in humans (14),
and potassium bromide seemed to be the most effective based on
response of dog owners.
By the time of submission, three dogs were euthanized at 9 mo,
2 y, and 5 y of age because of poor seizure control; three dogs died
from causes unrelated to the epilepsy and one died for unknown
reasons (Table S2). One dog was available for postmortem ex-
amination (case 2) that ruled out extracranial pathologies. In this
single brain, histology showed postictal changes only including mild
clustered neuronal hypereosinophilia in lateral geniculate nucleus
and pyramidal cell layers of the neocortex. Histoarchitectural
changes, dysmorphic neurons, and reactive gliosis were not evident.
The remaining dogs were alive without any evidence of mental or
cognitive decline.
Ambulatory Wireless Video EEG Defines the Electroclinical Syndrome.
Simultaneous video and EEG recordings documented the epi-
leptic origin of the events in 82% of examined cases (Table S2).
EEG was recorded for prolonged times (>1 h, 13 recording
leads) in 17 affected RRs displaying myoclonic twitches, and 11
breed-matched controls (10 healthy RRs, 1 RR with idiopathic epi-
lepsy with GTCS). Background activity was appropriate to state in all
dogs (15). Myoclonic twitches of variable intensity occurred in all but
two cases during EEG recording. The characteristic ictal pattern was
generalized 4–5 Hz spike-and-wave complexes (SWC) (Fig. 1 A
and B) or polyspike-wave complexes (PSWC) during the initial phase,
with a predominantly fronto-central maximum that often switched
between different leads over both hemispheres, and occasionally
generalized with a time lag. Another ictal pattern comprised biphasic
spikes and paroxysmal bursts consisting of 7- to 8-Hz spikes that at
times again were followed by SWC and an occasional occurrence of
focal activity (Fig. S1). In some dogs, myoclonic activity was consis-
tent with onset of ictal discharges, whereas in others myoclonic
twitches were preceded by a crescendo of EEG paroxysms. Not all
motor activity was accompanied by EEG paroxysms, but myoclonic
jerks appeared identical and muscle artifact may have obscured the
EEG correlate on some occasions. Affected RRs displayed also ep-
ileptiform discharges comprising ictal spikes or interictal 4- to 5-Hz
SWC (Fig. S1). Furthermore, some dogs intermittently displayed
rhythmical 4- to 5-Hz slowing that at times morphed into SWC ac-
companied by myoclonic jerks. During EEG recording, myoclonic
twitches emerged predominantly during quiet rest, drowsiness, or
slow-wave sleep. In some dogs, single episodes were recorded while
awake and even less often while standing. Similarly, EEG paroxysms
emerged with higher frequency when the dogs were less alert. The
effect of sleep deprivation was not assessed. For the EEG, instead of
sleep deprivation, we encouraged the dogs to nap. Unremarkable
EEG recordings were obtained from control dogs.
Photosensitivity Is a Feature of Generalized Myoclonic Epilepsy in RR
Dogs. Visually induced seizures were reported in 8 of 23 (35%;
confidence interval 95%: 18.7–55.2%) RRs with generalized
Fig. 1. Ictal EEG. LFF: 1 s; HFF: 70 Hz. (A and B) Minor head and eyelid twitches
were accompanied by 4-Hz spike-and-wave complexes with a central maximum
(A: Cz referential montage; B: bipolar montage). EEG is also presented as online
supporting material (Fig. S1 and Movie S4).
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myoclonic epilepsy (Table S2). These were described as myoclonic
seizures triggered by visual stimuli, such as light flashes, sudden
incidence of light when opening the shutters in the morning, or
sunlight interrupted by trees while walking through the forest. A
videotape was provided where each photic stimulus (produced by
photoflashes) was followed by myoclonic jerks (Movie S3). Upon
video-EEG recording with photic stimulation in six affected RRs,
four dogs (66%) displayed photoconvulsive responses time-locked
with the onset of the photic stimulus (Table S2 and Movie S4).
Video-EEG with photic stimulation did not reveal any abnormali-
ties in clinically healthy RR controls, including three heterozygous
carriers of the gene deletion. Besides light, noise was also a trig-
gering factor in three siblings (cases 8–10).
Genetic Analyses Reveal a 4-bp Deletion Mutation in DIRAS1. The
pedigree established around the affected dogs suggested an auto-
somal recessive inheritance (Fig. S2). To identify the genetic cause of
the generalized myoclonic epilepsy in RRs, we combined a genome
wide association study (GWAS) and next-generation sequencing
analyses using whole-exome (WES) and whole-genome (WGS)
resequencing. Assuming a recessive mode of inheritance, the WES
analysis of two unrelated cases against 169 exomes from nonepileptic
dogs (Table S3) resulted in a group of 10 variants, of which 6 were in
the predicted coding regions (Table S4). Only one nonsynonymous
variant was found, a 4-bp deletion in the exon 2 of the DIRAS1 gene
(c.564_567delAGAC; gene structure according to the Broad In-
stitute CanFam3 Improved Annotation Data v1) (Fig. 2D), resulting
in a frameshift and a stop loss (Fig. S3). A GWAS and haplotype
analysis in 10 RR cases and 18 RR controls supported the WES
study by identifying the best-associated region (P = 0.977 × 10−5)
(Table S5) in a 1.6-Mb region (55,597,243–57,195,857) at chromo-
some 20 (Fig. 2A), including theDIRAS1 gene (Fig. 2C). The critical
region was further split into a 300-kb and an 890-kb region (Fig. 2B)
by a 400-kb recombination in one of the cases. WGS of one epileptic
dog also identified the c.564_567delAGAC deletion in DIRAS1, but
it was absent from 99 control whole genomes (Table S3). Structural
variation analysis in the WGS data were performed within the
original 1.6-Mb associated region of the epileptic RR dog. Only one
35-kb duplication (56,210,949–56,246,523) was found in the region;
however, it resided outside of the 890-kb disease-associated haplo-
block, which starts at 56.3 Mb (Fig. 2B). In addition, the duplication
was present in several nonepileptic control dogs within our 99 dogs
WGS data (Table S3), excluding it as an epilepsy candidate in RRs.
The genotyping of the DIRAS1 deletion in 14 clinically verified
RR cases and 26 controls revealed a homozygous mutant ge-
notype in all cases, a heterozygous genotype in the obligate
carriers, and the homozygous wild-type genotype in controls
(Fig. 2D), indicating a complete segregation of the deletion allele
with the disease. Genotyping additional 498 RRs from 13
countries indicated a carrier frequency of ∼15% (Table S6). To
investigate the breed and epilepsy specificity of the deletion, we
genotyped an additional 965 epileptic dogs in 12 breeds, but did
not find any carriers, indicating that the mutation is specific to
generalized myoclonic epilepsy in RRs. Collectively, these results
strongly suggest that the deletion in the coding region of DIRAS1
causes the generalized myoclonic epilepsy in the breed.
Altered Intracellular Expression Pattern of Mutant DIRAS1. The ex-
pression pattern of the DIRAS1 transcript is poorly characterized
and suggested to be limited to the brain and heart (16). We
amplified the transcript in 28 canine tissues, including 12 brain
regions, the spinal cord, and 15 peripheral tissues, and found
abundant expression in all brain regions, whereas the pattern was
more limited and variable in extra neural tissues (Fig. S4). The
possible developmental expression pattern of DIRAS1 was also
investigated in the frontal cortices at six different time points: 2,
5, and 23 mo and 4, 5, and 9 y. The results indicate increased
expression until adulthood (Fig. 3A).
The 4-bp deletion resides at the end of the DIRAS1 coding
region, resulting in a frameshift at the C-terminal end of the
predicted protein (Fig. S3). The last 10 amino acids of DIRAS1
change causing a stop loss, which is followed by 104 extra amino
acids. The only functional domain, RAS, remains intact, but the
protein has additional low complexity regions toward its C ter-
minus (Fig. S3), likely rendering the mutated protein function-
ally altered. The effect of the deletion mutation on the stability
Fig. 2. GWAS. (A) Manhattan plot indicates best P values at chromosome 20. (B) An 890-kb haplotype is shared by cases. (C) The associated region contains 33
genes including DIRAS1. (D) Chromatograms of an affected, carrier, and wild-type dog indicate the c.564_567delAGAC variant.
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of the DIRAS1 transcript was investigated by quantitative PCR in
the frontal cortices between the age-matched 2-y-old case and
control dogs. The result suggested only a modest decrease in the
case (Fig. 3B), which also agrees with an unremarkable change in
the semiquantitative PCR (Fig. S4).
Immunolabeling revealed abundant expression of DIRAS1
antigen throughout the brain (brainstem, cerebellum, and pros-
encephalon), including the cholinergic basal forebrain nuclei,
depicted in Fig. 4. The intracellular expression pattern of wild-
type and mutant DIRAS1 somewhat differed between the single
affected dog and control dogs. Distinctive nuclear and mem-
branous pattern observed in the control dogs (RRs and non-
RRs) (Fig. 4 A and C) had changed to advanced diffuse staining
of nerve cell somata in the affected RR (Fig. 4 B and D). These
results suggest that there is a persistent expression of the mu-
tated DIRAS1 protein with an altered intracellular localization.
Discussion
This study characterizes a breed-specific generalized myoclonic
epilepsy with an early onset. Results from genetic and functional
studies suggest that the epilepsy is caused by a 4-bp deletion in
the coding region of the DIRAS1 gene, resulting in a frameshift and
a stop loss. We found abundant expression of DIRAS1 throughout
the canine brain with a difference in subcellular expression patterns
between wild-type and mutant proteins. Although mammalian
functions are unknown, previous studies suggest that DIRAS1 is
needed for acetylcholine transmission at neuromuscular junctions in
Caenorhabditis elegans (17) and neuronal development in zebrafish
(18). Therefore, this canine DIRAS1 defect provides not only a
candidate gene for generalized myoclonic epilepsies but also in-
sights to the disease etiology, while establishing a spontaneous
model for preclinical studies and functional characterization.
Common human idiopathic generalized epilepsies recognized
by the International League Against Epilepsy include childhood
absence epilepsy, epilepsy with myoclonic absences, epilepsy with
myoclonic atonic seizures, epilepsy with GTCS alone, juvenile
absence epilepsy, myoclonic epilepsy in infancy, and JME (19).
Generalized myoclonic epilepsy in RR dogs reveals important
parallels to JME, which is one of the most common forms of
epilepsy in humans (14, 20–23). As in humans, jerks are bilateral,
arrhythmic, at times asymmetric, and predominate upon the
upper limbs and trunk (20, 21), whereby additional nodding
movements of the head were present in some RRs. EEG re-
cordings revealed a pattern found in human JME patients: SW
or PSW discharges with a fronto-central accentuation and a
normal background activity with an occasional occurrence of
focal activity, EEG asymmetries switching sides, and diffuse or
intermittent slowing (22, 24, 25). An important characteristic
shared by human JME and generalized myoclonic epilepsy in
RRs is the manifestation with photosensitivity, particularly as
JME has one of the strongest associations with photosensitivity
among all epilepsies (26, 27). Phenotypic heterogeneity was ap-
parent because not all dogs were photosensitive, which may re-
flect influences of age, sex, or individual genetic background of
the dogs. In humans, photosensitivity is an age-dependent phe-
nomenon and is more prevalent in children with a peak age of
onset about 12 y (27). There is also strong evidence for a genetic
component of photoparoxysmal response (PPR) in humans and
many loci have been identified (27–30). Thus, affected RRs
provide another spontaneous large animal model to investigate
the neural mechanisms of photosensitivity (31, 32).
However, there are also a number of differentiating characteris-
tics and phenotypic heterogeneity: the low prevalence of GTCS
(JME 80–95%; RRs 38%), the absence of absence seizures (al-
though this seizure type might be difficult to recognize in dogs), and
Fig. 3. DIRAS1 expression. (A) The increase in the expression of the DIRAS1
transcript by age was observed when comparing six different age points in
the frontal cortex (the ages of 2 mo, 5 mo, 23 mo, 4 y and 10 mo, 5 y and
3 mo, and 9 y, n = 1 in each). (B) The stability of the DIRAS1 transcript was
studied in the frontal cortices of age-matched (24- and 23-mo-old) case (RR,
n = 1) and control (Great Dane, n = 1) dogs by a quantitative PCR. The result
suggests a modest decrease in the stability of the mutant transcript. The
error bars refer to variance in experimental triplicates (SD < 0.13 in each).
YWHAZ and GADPH were used as loading controls in quantitative PCR.
Fig. 4. ImmunohistochemicalDIRAS1 expression.Wild-type RRs show predominantly nuclear staining (black arrowhead) as seen in the parietal cortex (A; blue frame) and
cholinergic forebrain nuclei (C; black frame). With DIRAS1mutation (B and D) protein expression is abundant and there is a more diffuse staining of nerve cell perikarya
(white arrowhead) in all brain regions, including the brainstem. Figure shows expression in parietal cortex (B; blue frame), and forebrain nuclei (D; black frame). Cholinergic
target areas were confirmed by staining for the vesicular acetylcholine transporter (AChT), as demonstrated in the Inset. (Scale bar: A–D, 35 μm; inlet AChT, 150 μm.)
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a variable age of onset, with several dogs showing a relatively early
onset (6–10 wk) in the socialization period (6–12 wk) and others
during the juvenile period (starting at 12 wk) and adolescence up to
18 mo, when behavioral maturation tends to reach adult values in
the dogs (33–35). Differences between dog breeds exist and differ-
ences in the order of development of social and motor skills between
dogs and humans have been encountered (34). Thus, early age of
onset may still be in line with human genetic generalized epilepsy
syndromes, such as JME, in which 25% may have absence—and not
myoclonic—seizures in childhood. People with JME also have 2- to
3-Hz and 4- to 6-Hz interictal epileptic discharges, and most have
polyspikes (22). EEG failed to demonstrate clear ictal discharges in
association with myoclonus on some occasions. Although it was
considered that EEG was obscured by muscle artifact of the myoc-
lonus, myoclonic behavior needs to be monitored with telemetry for
further investigations. There is also a possibility that the generator
for myoclonic seizures is not superficial, rather subcortical. EEG
will not be able to detect deep neuronal function if the generator is
at the brainstem level. Although photosensitivity was observed in
35% of dogs, the prevalence of photosensitivity based upon the EEG
studies appears to be higher (66%) than in humans and, in humans,
the photoparoxysmal and photoconvulsive responses are maximal
fronto-centrally and not occipitally. There is a high prevalence of
MRI findings, which is not typical for human JME.We acknowledge
that the presence of MRI findings point toward a symptomatic eti-
ology; however, there were no consistent findings. Ventricle asym-
metry is also frequently present in dogs without epileptic seizures,
and thus may be clinically not relevant (12). Similarly, a small
amount of meningeal enhancement is consistently demonstrated in
normal dogs (36). However, we cannot exclude that some of the
structural abnormalities interacted with the phenotype: for example,
lowered seizure threshold on both hemispheres. The EEG pheno-
type is consistent with generalized myoclonic epilepsy, and certainly
not focal epilepsy. Finally, human JME is characterized by strong
chronodependency, with myoclonic jerks and GTCS in the morning
after awakening or during relaxation periods in the evening (37).
Although generalized myoclonic epilepsy in RRs also shows a strong
association with the sleep–wake cycle, myoclonic twitches and EEG
discharges appeared predominantly in the relaxed state, at rest, or
during the first stages of sleep, mirroring subtypes of JME (38). The
observed differences may reflect species-specific differences in bio-
rhythmicity and sleep regulation, or may indicate parallels to other
genetic sleep-associated epilepsies, such as myoclonic epilepsy in
infancy, which sometimes progresses to JME (39), or autosomal
dominant nocturnal frontal lobe epilepsy (NFLE) (40).
DIRAS1 is a novel epilepsy gene with a robust expression pattern
in the CNS tissues. It is part of the Ras family of small GTPases,
which have been linked to many cellular signaling pathways in cell
growth and differentiation, synaptic plasticity, learning, and memory
(41–43). DIRAS1 and DIRAS2 form a biochemically and func-
tionally distinct branch of Ras GTPases, which are character-
ized by a fast guanidine–nucleotide exchange rate (16). The
biological function of DIRAS1 in mammals is poorly characterized.
DIRAS1 has been suggested to function as a tumor suppressor in
glioblastoma and other tumor cell lines through the inhibition of
Ras-mediated transformation, altered NF-κB transcription activity,
diminished ERK1/2 and MAPK signaling, and antagonization of
pro-oncogenic small Ras GTPases (44). Studies in C. elegans have
demonstrated that the DIRAS1 and exchange protein directly ac-
tivated by cAMP (EPAC) orthologs colocalize at the presynaptic
membranes and are needed for the maintenance of normal pre-
synaptic acetylcholine release at neuromuscular junctions (17).
DIRAS1 was also suggested to play a role in cell migration, neurite
outgrowth, and dendrite architecture in the developing nervous
system of a zebrafish model (18).
Understanding the role and mechanisms of DIRAS1 in cho-
linergic neurotransmission and epilepsy remains an important
task. Nicotinergic cholinergic activity influences brain excitability
and cognition, regulates the excitatory/inhibitory switch of GABA
during neuronal development (45), stimulates glutamate release
from thalamocortical terminals, controls GABA release onto py-
ramidal neurons, and maintains nonrapid eye movment sleep by low
levels of acetylcholine, whereby cholinergic stimulation is associated
with microarousals in this sleep stage (46). Mutations in nicotinergic
acetylcholine receptor (nAChR) subunits CHRNA4, CHRNA2, and
CHRNB2 are associated with autosomal dominant NFLE and
sporadic NFLE (47). CHRNA7 coding for the α7 subunit of the
nAChR is also a potential candidate gene for JME in humans (48).
Abnormal DIRAS1 function could alter cholinergic neurotrans-
mission or formation of neuronal circuits and network assembly in
the developing brain resulting in myoclonic epilepsy and photo-
sensitivity. This canine model establishes a prime resource to ad-
dress these questions and mechanisms in future experiments,
including mutation-specific–induced neuronal cultures.
In summary, careful clinical and genetic studies identified a
candidate gene for one of the most common forms of human
epilepsy with a postulated function in cholinergic neurotrans-
mission. While inspecting the gene in human myoclonic and
epilepsy cohorts for risk variants, future functional studies should
identify the DIRAS1-mediated mechanisms in neurotransmis-
sion and provide drug targets for common epilepsies.
Materials and Methods
Study Cohorts. Twenty-four RR cases were identified (Table S2). Inclusion criteria
were clinical observation of myoclonic jerks on video recordings or observation at
one of the study sites and completion of an online questionnaire or an interview.
Altogether, 538 EDTA-blood and tissue samples were collected from privately
owned RRs in Germany, Finland, and 11 other countries (Table S6). A cohort of 965
epileptic dogs from 12 other breeds from Finland was included (Table S6). Sample
collection was ethically approved by the Animal Ethics Committee of State Pro-
vincial Office of Southern Finland, Hämeenlinna, Finland (ESAVI/6054/04.10.03/
2012), “Cantonal Committee for Animal Experiments” (Canton of Bern; permit
23/10), and the German Animal Welfare Act. Further details are provided in
SI Materials and Methods.
Neurodiagnostic Investigation. All RR cases underwent a clinical, neurological,
and laboratory examination. Structural epilepsy was excluded by imaging
throughMRI in 12 RR cases and postmortem examination of 1 dog. Additional
investigations comprising cerebrospinal fluid (CSF) analysis, neurometabolic
screening, imaging through CT, skin biopsy, and AED serum concentration
measurements were performed for a number of studied dogs. Further details
are provided in SI Materials and Methods.
EEG. Awake ambulatory wireless video-EEG was conducted in 17 RR cases and
11 RR control dogs. Recordings were performed in a quiet environment, with
dogs encouraged to lie down. EEG was recorded routinely using 15 (7 in one
dog) subdermal needle electrodes. In six cases and four controls an additional
video-EEGwith photic stimulationwas conducted at the end of the EEG study.
Further details are provided in SI Materials and Methods.
Postmortem Examination. Postmortem examination was conducted on one
affected RR. The animal underwent routine autopsy in which the brain was
removed in toto and trimmed according to standardized algorithms (49).
Relevant brain areas (prosencephalon, cerebellum, brainstem) were sampled
and histologically evaluated using neurohistological standard stains on
paraffin sections.
GWAS. Genotyping of 10 affected RRs from the initial study cohort and 18
unaffected RRs was performed. The genotype data were filtered and fre-
quency and genotyping pruned. A case-control association test was per-
formed by PLINK (50) and by Mendel software’s Ped-GWAS (51). Further
details are provided in SI Materials and Methods.
Resequencing.Dogexome libraries for twoGermanRRcasesweregenerated. The
sequencing data were analyzed and filtered under a recessive model against 169
additional exomes (Table S3). The pathogenicity of the coding variants was
predicted in the CanFam 3.1 annotation. One RR case was whole-genome se-
quenced and filtered against 99 additional whole genomes (Table S3) and the
presence of the candidate mutation was inspected visually. Further details are
provided in SI Materials and Methods.
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Sanger Sequencing and TaqMan Genotyping. The identified candidate variant
was validated by a standard PCR followed by Sanger sequencing in 33German
RR samples, including 12 cases from the initial study cohort. For a larger
mutation screening in additional samples (Table S6), a TaqMan assay was run.
Further details are provided in SI Materials and Methods.
Gene Expression. Fresh postmortem samples were collected (for the full list,
see Fig. 3 and Fig. S4) from one case and six control dogs. RNA was extracted
and reverse-transcribed into cDNA. The canine DIRAS1 transcript was am-
plified and sequenced. Semiquantitative and quantitative PCRs were per-
formed. Further details are provided in SI Materials and Methods.
Immunohistochemistry. Tissue studies were conducted on the brains (pros-
encephalon, cerebellum, brainstem) of one RR case and three control RRs
(LMU Munich neuropathology brain archive). Primary antibodies (pAB) were
directed at DIRAS1 and the vesicular acetylcholine transporter. The slides
were antigen-demasked, incubated with pAB, and stained using polymer
technology and a diaminobenzidine tetrahydrochloride. Further details are
provided in SI Materials and Methods.
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